<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117481</article-id><article-id pub-id-type="publisher-id">ACM-44230</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_44865297.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  心脏起搏导线植入位置演变
  The Change of Cardiac Pacing Leads Location
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邹</surname><given-names>春霞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>伟新</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>南华大学衡阳医学院，湖南 衡阳</addr-line></aff><aff id="aff3"><addr-line>中国医学科学院阜外医院深圳医院，广东 深圳</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3308</fpage><lpage>3314</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  1958年，因严重心动过缓植入了第一枚起搏器。1970年，第一次提出用一种设备(如除颤器)预防心脏性猝死。经历50余年的发展，人们越来越多的认识到起搏导线相关的并发症及导线位置对远期预后的影响，研发了CRT起搏器、无导线起搏器、全皮下埋藏式心脏复律除颤器；希氏术起搏及左束支区域起搏是起搏发展史上的里程碑。
   The first pacemaker was implanted in 1958 for severe symptomatic bradycardia. The concept of a device to avert sudden cardiac death (i.e., the defibrillator) was first published in 1970. After more than 50 years of development, people are aware of the complications associated with pacing leads and the influence of lead location on long-term prognosis. Cardiac Resynchronisation Therapy, leadless pacemakers, and subcutaneous implantable cardioverter-defibrillator have been developed. His bundle pacing and left bundle branch area pacing are milestones in the history of pacemaker.
 
</p></abstract><kwd-group><kwd>导线，无导线起搏器，全皮下埋藏式心脏复律除颤器，左束支区域起搏, Leads</kwd><kwd> Leadless Pacemakers</kwd><kwd> Subcutaneous Implantable Cardioverter-Defibrillator</kwd><kwd> 
Left Bundle Branch Area Pacing</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>1958年，因严重心动过缓植入了第一枚起搏器。1970年，第一次提出用一种设备(如除颤器)预防心脏性猝死。经历50余年的发展，人们越来越多的认识到起搏导线相关的并发症及导线位置对远期预后的影响，研发了CRT起搏器、无导线起搏器、全皮下埋藏式心脏复律除颤器；希氏术起搏及左束支区域起搏是起搏发展史上的里程碑。</p></sec><sec id="s2"><title>关键词</title><p>导线，无导线起搏器，全皮下埋藏式心脏复律除颤器，左束支区域起搏</p></sec><sec id="s3"><title>The Change of Cardiac Pacing Leads Location<sup> </sup></title><p>Chunxia Zou<sup>1</sup>, Weixin Chen<sup>2*</sup></p><p><sup>1</sup>Hengyang Medical College, University of South China, Hengyang Hunan</p><p><sup>2</sup>Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen Guangdong</p><p><img src="//html.hanspub.org/file/62-1572263x4_hanspub.png?20210729084600098" /></p><p>Received: Jun. 26<sup>th</sup>, 2021; accepted: Jul. 19<sup>th</sup>, 2021; published: Jul. 28<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/62-1572263x5_hanspub.png?20210729084600098" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>The first pacemaker was implanted in 1958 for severe symptomatic bradycardia. The concept of a device to avert sudden cardiac death (i.e., the defibrillator) was first published in 1970. After more than 50 years of development, people are aware of the complications associated with pacing leads and the influence of lead location on long-term prognosis. Cardiac Resynchronisation Therapy, leadless pacemakers, and subcutaneous implantable cardioverter-defibrillator have been developed. His bundle pacing and left bundle branch area pacing are milestones in the history of pacemaker.</p><p>Keywords:Leads, Leadless Pacemakers, Subcutaneous Implantable Cardioverter-Defibrillator, Left Bundle Branch Area Pacing</p><disp-formula id="hanspub.44230-formula35"><graphic xlink:href="//html.hanspub.org/file/62-1572263x7_hanspub.png?20210729084600098"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/62-1572263x8_hanspub.png?20210729084600098" /> <img src="//html.hanspub.org/file/62-1572263x9_hanspub.png?20210729084600098" /></p></sec><sec id="s5"><title>1. 心脏起搏简史</title><p>现代意义上的起搏器首次使用是在20世纪20年代末。到了1932年，Albert Hyman发明了第一个人工心脏起搏器，并创造了“人工心脏起搏器”这个词 [<xref ref-type="bibr" rid="hanspub.44230-ref1">1</xref>]。</p><p>1950年，心脏起搏领域出现重大突破，PaulZoll创造了一个经皮的体外起搏系统，这个系统至今仍在紧急情况下使用 [<xref ref-type="bibr" rid="hanspub.44230-ref2">2</xref>]。随着心脏外科手术领域的迅速发展，常见的并发症是His束损伤并导致房室传导阻滞。直接连接在心脏上的电极可以与外部脉冲发生器相连以刺激心脏，使传导得以恢复。来自明尼苏达大学的C Walton Lillehei和Earl Bakken开发了一种体外电池供电的起搏器，使系统更加可靠和便携 [<xref ref-type="bibr" rid="hanspub.44230-ref3">3</xref>]。</p><p>1958年，Ake Senning植入第一台完全植入式心脏起搏器。第一个接受这种起搏器的患者Arne Larsson一生中共接受了26次起搏器手术，并在86岁时去世 [<xref ref-type="bibr" rid="hanspub.44230-ref4">4</xref>]。电池技术、脉冲发生器的大小和可编程性以及静脉组件的使用等方面的后续改进，促使现代起搏器系统的出现。</p></sec><sec id="s6"><title>2. 现代起搏系统的局限性及存在的问题</title><p>目前的经静脉起搏系统包括脉冲发生器、连接脉冲发生器及心肌的导线。最重要的适应症是症状性心动过缓。然而，在过去的50年里，整体的设计并没有明显的变化。整个系统的许多局限性和临床并发症与其整体的设计及构造有关，尤其是与导线有关。导线包裹着绝缘层，心脏和肩膀的运动产生的机械应力可能导致导线断裂。脉冲发生器位于皮下组织间隙、血管外，可能成为细菌感染的病灶，而导线将成为细菌血行感染的门户。另一方面，心室起搏导线被认为是症状性三尖瓣反流的罪魁祸首。普通起搏器、经静脉系统植入的ICD (implantable cardioverter-defibrillator)、CRT (cardiac resynchronization therapy)等心室导线相关的三尖瓣反流及少部分三尖瓣狭窄，成为造成三尖瓣功能受损的重要原因。近年来这个问题越来越受到关注，原因是人们逐渐意识到三尖瓣反流是一个不能忽略的问题 [<xref ref-type="bibr" rid="hanspub.44230-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.44230-ref6">6</xref>]。还有一个研究热点是传统起搏器植入术的并发症。起搏器植入的并发症可分为术中、术后早期和晚期并发症，需要迅速的识别及处理。术中并发症包括气胸、血胸、胸壁血肿、心脏穿孔和导线脱位。术后早期并发症包括囊袋感染、静脉血栓形成或静脉狭窄、三尖瓣机械性损伤及反流、心室起搏引起的心前区不适等。晚期并发症包括导线断裂或绝缘层破损，起搏阈值或阻抗升高，以及起搏器囊袋感染及血行感染。晚期并发症的治疗往往是复杂的，可能需要拔除导线。拔除导线的技术具有一定的挑战性，有中心静脉或心脏穿孔、血胸的风险乃至死亡。</p><p>最初的心脏起搏为固律型VOO起搏器；1966年后发展为按需型VVI起搏器。80年代后期，双腔DDD起搏器正式开始在临床应用。DDD模式能保证房室顺序起搏，与单腔VVI起搏器相比，使心房充分发挥辅助泵的作用，合并频率应答功能的起搏器能满足患者在不同情况下的生理性需要。然而，CTOPP [<xref ref-type="bibr" rid="hanspub.44230-ref7">7</xref>]、MOST [<xref ref-type="bibr" rid="hanspub.44230-ref8">8</xref>]、UKPACE [<xref ref-type="bibr" rid="hanspub.44230-ref9">9</xref>] 等大规模临床实验的结果提示，如果DDD工作模式下心室电极植入位点位于右室心尖部，同时心室起搏比例过高，则将增加因心室负荷改变和电传导顺序改变而带来的患者死亡率上升的风险，抵消了DDD模式保持房室同步及变时性所带来的益处。人们在开始研发最大限度减少不良性心室起搏的带有生理性起搏功能的脉冲发生器的同时 [<xref ref-type="bibr" rid="hanspub.44230-ref10">10</xref>]，将关注点投入到调整心室起搏导线的位置，保证心室同步化起搏。</p></sec><sec id="s7"><title>3. 心脏起搏导线的革命</title><sec id="s7_1"><title>3.1. 起搏导线的植入位置</title><p>传统的右室心尖部起搏(right ventricular apex pacing, RVAP)造成左室泵血功能下降，二尖瓣返流，心室重构,最终导致心力衰竭。鉴于RVAP 的不良影响，其他起搏位点的研究得到开展。包括右室间隔部起搏、右室双部位起搏、双心室同步起搏等。双心室同步起搏即心脏再同步化治疗(cardiac resynchronization therapy, CRT) 对于有心力衰竭和心室失同步的患者有着重要作用。右室间隔部起搏包括(1) 右室希氏束起搏(his-bundle pacing, HBP)；(2) 左束支区域起搏(left bundle branch area pacing, LBBAP)；(3) 右室流入道起搏；(4) 右室流出道间隔部起搏(right ventricular outflow tact septal pacing, RVOTSP)；(5) 右室中间隔部起搏(right ventricular midseptal pacing, RVMSP)。针对后三者的研究并未得出明显优于RVAP的一致结论 [<xref ref-type="bibr" rid="hanspub.44230-ref11">11</xref>]。</p></sec><sec id="s7_2"><title>3.2. 心脏再同步化治疗(Cardiac Resynchronisation Therapy, CRT)</title><p>心脏左室的非同步化运动出现在左室电活动延迟导致左室收缩不同步，大多数发生在合并完全性左束支传导阻滞患者的左室侧壁。CRT通过对延迟运动的心室肌的靶向的电刺激以达到提高电和机械同步的效应，由右室心尖部的导线和植入冠状窦的左室导线同时起搏完成，部分患者左室导线固定于左室心外膜。然而，CRT并不总是有效，大约30%的患者对该治疗无反应。因此，临床术者应遵从目前现有的指南严格挑选CRT治疗的患者以及确保左室导线送至靶血管以最大化CRT的治疗效果 [<xref ref-type="bibr" rid="hanspub.44230-ref12">12</xref>]。如何提高CRT应答率是目前临床医师面临的主要难题之一。</p><sec id="s7_2_1"><title>3.2.1. 四极导线及多位点起搏</title><p>四极导线是CRT领域近年最重要的进展成果。四极导线通过相互组合，提供多种起搏向量组合，寻找最佳起搏位点，不仅提高手术成功率，缩短手术时间，而且有效避免膈神经刺激，减少左室高起搏阈值等可能。这种多位点起搏治疗可以捕获左室更多的心肌，进一步改善左室同步性，从而提高CRT应答率。与双极导线相比，四极导线有更低的导线更换或旷置率，并且降低了死亡率 [<xref ref-type="bibr" rid="hanspub.44230-ref13">13</xref>]。然而，2019年发表的一项纳入了1921例患者的研究显示，多位点起搏对CRT无反应的患者没有初步疗效 [<xref ref-type="bibr" rid="hanspub.44230-ref14">14</xref>]。我们需要这项研究的II期数据以及其他正在进行的研究的数据去评估多位点起搏是否在CRT无应答患者中有显著的优势。</p></sec><sec id="s7_2_2"><title>3.2.2. 左室心内膜起搏(Left Ventricular Endocardial Pacing, LVEP)</title><p>传统的冠状窦左室电极即便植入成功，也有可能因多种原因导致无应答，而且本质上是一种非生理性起搏，因为正常情况下除极顺序应从心内膜向心外膜除极。而且，经冠状窦的左室电极植入依赖于冠状静脉系统的解剖，部分患者可能无法寻找到适合的靶血管。基于此，经锁骨下静脉途径穿刺房间隔植入左室电极进行左室心内膜起搏的技术应运而生。前瞻性、国际多中心的ALSYNC研究 [<xref ref-type="bibr" rid="hanspub.44230-ref15">15</xref>] 评估了左室心内膜起搏技术的可行性及安全性。结果发现，LVEP电极植入成功率89%。与传统的经冠状窦植入左室导线相比，可以获得更佳的夺获阈值和较低的膈神经刺激发生率。该项技术的主要并发症是血栓栓塞并发症，包括肺栓塞、脑栓塞等，术后需要长期抗凝；此外，左室心内膜电极经房间隔跨二尖瓣进入左室，造成二尖瓣关闭不全和增加感染性心内膜炎等风险。</p></sec></sec><sec id="s7_3"><title>3.3. 希氏束起搏(His Bundle Pacig, HBP)</title><p>His束起搏引起的电活动与正常心室激动顺序一致，理论上是最好的心室起搏部位。HBP最早可追溯至1967年，由Scherlag [<xref ref-type="bibr" rid="hanspub.44230-ref16">16</xref>] 等首次提出。2000年，Deshmukh等首次报道了人体永久性HBP，证实了该项技术可行、安全、有效。2004年，该作者扩大样本量，入组的54例患者均为扩张型心肌病。其中36例接受DHBP，随访时间42个月，证实HBP 明显改善左室功能 [<xref ref-type="bibr" rid="hanspub.44230-ref17">17</xref>]。同时Deshmukh最早建立了相对完整的HBP标准 [<xref ref-type="bibr" rid="hanspub.44230-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.44230-ref18">18</xref>]。根据起搏夺获位点，分为直接HBP (direct his bundle pacing, DHBP)和His束旁起搏(para his bundle pacing, PHBP)。由于直接HBP的定位和电极固定难度较大，手术时间较长，起搏阈值高(&gt;2 V [<xref ref-type="bibr" rid="hanspub.44230-ref18">18</xref>] )，导致需要更加耗用电池电流，从而减短起搏器寿命，同时，直接HBP存在潜在的损伤或阻断希氏束可能，可能需要在右室心尖部或流出道植入备用电极以避免心脏停搏，因此限制了该术式在临床的推广应用。尽管如此，HBP的临床研究相继展开，绝大部分研究证实HBP优于RVAP [<xref ref-type="bibr" rid="hanspub.44230-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.44230-ref20">20</xref>]。前瞻性的IMAGE-HBP研究纳入61例患者成功实现希氏束起搏，随访12个月，无导线相关并发症比例达93% [<xref ref-type="bibr" rid="hanspub.44230-ref21">21</xref>]。设计更多的递送系统工具及进一步改进起搏导线可能增加希氏束电极植入的成功率(类似于左室电极冠状窦递送系统)。</p></sec><sec id="s7_4"><title>3.4. 左束支区域起搏(Left Bundle Branch Area Pacing, LBBAP)</title><p>希氏束起搏虽然经历了近20年的发展，但目前为止仍然无法完全解决高阈值、P波过感知等问题，而且学习曲线长、手术X线曝光时间长 [<xref ref-type="bibr" rid="hanspub.44230-ref22">22</xref>]，部分患者尚需要在右室心尖部或流出道植入备用电极。2017年，黄伟剑教授等人 [<xref ref-type="bibr" rid="hanspub.44230-ref23">23</xref>] 报告了第一例左束支区域起搏病例，证实了这种新型的起搏技术除了能纠正典型的完全性左束支传导阻滞外，还具有稳定的低阈值(0.5 V/0.5ms)。随后，这项技术开始蓬勃发展。与HBP比较，LBBAP在获得更窄的QRS波的同时，起搏阈值更低、更稳定。房室传导阻滞、可能进展为心室起搏依赖及完全性左束支传导阻滞合并心功能下降等均为重要适应症。由Pugazhendhi Vijayaraman教授主导的国际LBBP合作小组 [<xref ref-type="bibr" rid="hanspub.44230-ref24">24</xref>] 纳入325例有CRT治疗指征的患者，用以评估LBBP在该类患者中的可行性及效果。其中85%的患者成功实现CRT。总手术时间为(105 &#177; 54) min，术中曝光时间为(19 &#177; 16) min，术中LBBP导线阈值为(0.76 &#177; 0.50) V/0.5ms，R波振幅为(11.5 &#177; 6.8) mV，术后测量QRS波时限(137 &#177; 22) ms较术前(156 &#177; 32) ms明显缩窄(P &lt; 0.0001)。该研究提示对于有CRT植入适应症的患者而言，LBBP是可行且安全的一种选择。LBBP不仅提供了稳定的低阈值，而且改善了超声心动图及临床结局。</p><p>鉴于对传统的经静脉的普通起搏器、ICD的起搏导线带来的并发症的认识，催生了全皮下埋藏式心脏复律除颤器及无导线起搏器。</p></sec></sec><sec id="s8"><title>4. 全皮下埋藏式心脏复律除颤器与无导线心脏起搏器</title><sec id="s8_1"><title>4.1. 全皮下埋藏式心脏复律除颤器 (Subcutaneous Implantable Cardioverter-Defibrillator, S-ICD)</title><p>1980年首次将ICD成功植入人体，开启了心源性猝死治疗的一个新时代。长期以来的临床证据已证明ICD可以降低多种致心源性猝死疾病的死亡率，ICD已成为预防心源性猝死的主要治疗手段。传统的ICD系统是通过外周静脉送入ICD导线至右心室，并与埋藏在左胸部皮下的脉冲发生器相联，除颤电极导线在静脉及心腔内。经静脉ICD除了有除颤复律功能外，还有起搏功能。传统的ICD平均寿命约5.9年，对年轻的患者而言可能需要多次更换起搏器脉冲发生器。传统的经静脉ICD的长期并发症是感染风险。而更换脉冲发生器时感染风险比首次安装时翻倍。起搏器系统感染对患者是灾难性后果，涉及到可能需要取出电极。另一个顾虑是电极功能不良，一项长期研究提示，10年时电极的年故障率达20% [<xref ref-type="bibr" rid="hanspub.44230-ref25">25</xref>]；电极功能不良虽然不是绝对需要拔除电极，但极有可能是首选的处理方式，而取出长期放置的经静脉电极尤其是除颤电极，是一个有潜在并发症及死亡风险的操作。2012年，美国FDA批准S-ICD用于解决一些经静脉ICD (TV-ICD)产生的并发症。S-ICD可避免高活动量导致的电极损坏，适合多次更换，降低了拔除电极风险，且遇到静脉入路缺失的先天性心脏病患者，慢性静脉闭塞、儿科、需要静脉做透析的患者，以及三尖瓣置换术后的患者不太适合静脉系统植入ICD，如这类患者合并猝死高风险且无起搏依赖时均可选择S-ICD。2020年5月第41届美国心律学年会公布了两项关于S-ICD的临床试验初步结果。PRAETORIAN试验 [<xref ref-type="bibr" rid="hanspub.44230-ref26">26</xref>] 是一项国际多中心、随机、非劣效性试验。该试验总共纳入849例具有ICDIa或IIa类适应证患者，其共同特点是不需起搏、CRT治疗或抗心动过速起搏治疗；其中S-ICD组426例，TV-ICD组423例，平均随访49.1个月，最终结果提示，在有ICD适应症但不需起搏的患者中，导线相关的并发症发生率S-ICD组显著低于TV-ICD组。S-ICD组与TV-ICD组全因死亡的差异无统计学意义。另一项纳入了国际多中心1116例患者的前瞻性、非对照的UNTOUCHED试验 [<xref ref-type="bibr" rid="hanspub.44230-ref27">27</xref>] 跟以往的S-ICD研究纳入的患者情况不同，该试验主要是纳入典型的具备ICD植入适应症的左室射血分数 &lt; 35%且不需起搏治疗的一级预防人群同时进行定期规范的程控及改进恶性心律失常识别功能的鉴别算法，而以往的研究所纳入的人群合并症更少、左室心功能不全相对较少、而且不恰当电击(inappropriate shocks, IAS)相比植入TV-ICD的患者更多。结果证明了新一代的S-ICD系统及识别恶性心律失常、恰当电击治疗的有效性及安全性，与既往的发表的S-ICD研究比较，IAS发生率最低(3.1%/年)，同时比许多按照目前程控算法的TV-ICD植入患者的IAS发生率都低。因此，对于不需起搏的一级预防的ICD植入患者，新一代的S-ICD同样安全有效。</p></sec><sec id="s8_2"><title>4.2. 无导线心脏起搏器(Leadless Pacemaker)</title><p>无导线心脏起搏象征着起搏系统设计的飞跃式创新，目的是创造体积小、不需连接经静脉起搏导线以及无需关联任何血管外的组件的可植入心脏内的起搏器。Micra无导线起搏器的安全性和有效性已在多项临床试验中得到证明，而Micra证据发展覆盖率研究(CED) [<xref ref-type="bibr" rid="hanspub.44230-ref28">28</xref>] 比较了美国植入Micra无导线VVI起搏器(M-VVI)和经静脉VVI起搏器患者(TV-VVI)的特征和慢性(6个月)并发症，包括导线脱位、感染和囊袋并发症。最终得出的结论是，在真实的临床情景下，尽管M-VVI患者合并症更多，但与同期TV-VVI的患者相比，其慢性并发症的风险减少了66%。</p></sec></sec><sec id="s9"><title>5. 结论</title><p>心脏起搏器导线从开始的单腔VOO心室导线到心房心室双腔DDD模式，从右室心尖部起搏到右室流出道间隔部起搏，从单心室起搏到双心室起搏，再到希氏术起搏及左束支区域起搏，最后到无导线起搏器及全皮下ICD，这一系列的演变过程，是人类探索心脏起搏器在预防灾难性的心动过缓事件、猝死事件及改善心力衰竭的必由之路。</p></sec><sec id="s10"><title>文章引用</title><p>邹春霞,陈伟新. 心脏起搏导线植入位置演变The Change of Cardiac Pacing Leads Location[J]. 临床医学进展, 2021, 11(07): 3308-3314. https://doi.org/10.12677/ACM.2021.117481</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44230-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Hyman, A.S. (1932) Resuscitation of the Stopped Heart by Intracardial Therapy. Experimental Use of an Artificial Pacemaker. Archives of Internal Medicine, 50, 283-305. &lt;br&gt;https://doi.org/10.1001/archinte.1932.00150150115012</mixed-citation></ref><ref id="hanspub.44230-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Zoll, P.M. (1952) Resuscitation of the Heart in Ventricular Standstill by External Electric Stimulation. The New England Journal of Medicine, 247, 768-771. &lt;br&gt;https://doi.org/10.1056/NEJM195211132472005</mixed-citation></ref><ref id="hanspub.44230-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Aquilina, O. (2006) A Brief History of Cardiac Pacing. Images in Paediatric Cardiology, 8, 17-81.</mixed-citation></ref><ref id="hanspub.44230-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Altman, L.K. (2002) Arne H. W. Larsson, 86, Had First Internal Pacemaker. New York Times, 18 January 2002.</mixed-citation></ref><ref id="hanspub.44230-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Dreyfus, G.D., Corbi, P.J., Chan, K.M. and Bahrami, T. (2005) Secondary Tricuspid Regurgitation or Dilation: Which Should Be the Criteria for Surgical Repair? The Annals of Thoracic Surgery, 79, 127-132.  
&lt;br&gt;https://doi.org/10.1016/j.athoracsur.2004.06.057</mixed-citation></ref><ref id="hanspub.44230-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Nath, J., Foster, E. and Heidenreich, P.A. (2004) Impact of Tricuspid Regurgitation on Long-Term Survival. Journal of the American College of Cardiology, 43, 405-409. &lt;br&gt;https://doi.org/10.1016/j.jacc.2003.09.036</mixed-citation></ref><ref id="hanspub.44230-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Conno lly, S.J., Kerr, C.R., Gent, M., et al. (2000) Effects of Physiologic Pacing versus Ventricular Pacing on the Risk of Stroke and Death Due to Cardiovascular Causes: Canadian Trial of Physiologic Pacing Investigators. The New England Journal of Medicine, 342, 1385-1391. &lt;br&gt;https://doi.org/10.1056/NEJM200005113421902</mixed-citation></ref><ref id="hanspub.44230-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Lamas, G.A., Lee, K.L., Sweeney, M.O., et al. (2002) Mode Selection Trial in Sinus-Node Dysfunction: Ventricular Pacing or Dual Chamber Pacing for Sinus-Node Dysfunction. The New England Journal of Medicine, 346, 1854-1862.</mixed-citation></ref><ref id="hanspub.44230-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Toff, W.D., Skehan, J.D., De Bono, D.P., et al. (1997) The United Kingdom Pacing and Cardiovascular Events (UKPACE) Trial United Kingdom Pacing and Cardiovascular Events. Heart, 78, 221-223.  
&lt;br&gt;https://doi.org/10.1136/hrt.78.3.221</mixed-citation></ref><ref id="hanspub.44230-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Sweeney, M.O., Bank, A.J., Nsah, E., Koullick, M., Zeng, Q.C., Hettrick, D., Sheldon, T., Lamas, G.A. and Search, A.V. (2007) Extension and Managed Ventricular Pacing for Promoting Atrioventricular Conduction (SAVE PACe) Trial. Minimizing Ventricular Pacing to Reduce Atrial Fibrillation in Sinus-Node Disease. The New England Journal of Medicine, 357, 1000-1008. &lt;br&gt;https://doi.org/10.1056/NEJMoa071880</mixed-citation></ref><ref id="hanspub.44230-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Domenichini, G., Sunthorn, H., Fleury, E., et al. (2012) Pacing of the Interventricular Septum versus the Right Ventricular Apex: A Prospective, Randomized Study. European Journal of Internal Medicine, 23, 621-627.  
&lt;br&gt;https://doi.org/10.1016/j.ejim.2012.03.012</mixed-citation></ref><ref id="hanspub.44230-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Russo, A.M., Stainback, R.F., et al. (2013) ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 61, 1318-1368. &lt;br&gt;https://doi.org/10.1016/j.jacc.2012.12.017</mixed-citation></ref><ref id="hanspub.44230-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Turakhia, M.P., Cao, M., Fischer, A., et al. (2016) Reduced Mortality Associated with Quadripolar Compared to Bipolar Left Ventricular Leads in Cardiac Resynchronization Therapy. JACC: Clinical Electrophysiology, 2, 426-433.  
&lt;br&gt;https://doi.org/10.1016/j.jacep.2016.02.007</mixed-citation></ref><ref id="hanspub.44230-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Leclercq, C., Burri, H., Curnis, A., et al. (2019) Cardiac Resynchronization Therapy Non-Responder to Responder Conversion Rate in the More Response to Cardiac Resynchronization Therapy with Multipoint Pacing (MORE-CRT MPP) Study: Results from Phase I. European Heart Journal, 40, 2979-2987. &lt;br&gt;https://doi.org/10.1093/eurheartj/ehz109</mixed-citation></ref><ref id="hanspub.44230-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Morgan, J.M., Biffi, M., Geller, L., et al. () Alternate Site Cardiac ResYNChronization (ALSYNC): A Prospective and Multicentre Study of Left Ventricular Endocardial Pacing for Cardiac Resynchronization Therapy. European Heart Journal, 37, 2118-2127. &lt;br&gt;https://doi.org/10.1093/eurheartj/ehv723</mixed-citation></ref><ref id="hanspub.44230-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Scherlag, B.J., Kosowsky, B.D. and Damato, A.N. (1967) A Technique for Ventricular Pacing from the His Bundle of the Intact Heart. Journal of Applied Physiology, 22, 584. &lt;br&gt;https://doi.org/10.1152/jappl.1967.22.3.584</mixed-citation></ref><ref id="hanspub.44230-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Deshmukh, P.M. and Romanyshyn, M. (2004) Direct His-Bundle Pacing: Present and Future. Pacing and Clinical Electrophysiology, 27, 862. &lt;br&gt;https://doi.org/10.1111/j.1540-8159.2004.00548.x</mixed-citation></ref><ref id="hanspub.44230-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Deshmukh, P., Casavant, D.A., Romanyshyn, M., et al. (2000) Permanent, Direct His-Bundle Pacing: A Novel Approach to Cardiac Pacing in Patients with Normal His Purkinje Activation. Circulation, 101, 869.  
&lt;br&gt;https://doi.org/10.1161/01.CIR.101.8.869</mixed-citation></ref><ref id="hanspub.44230-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Catanzariti, D., Maines, M., Manica, A., et al. (2013) Permanent His-Bundle Pacing Maintains Long-Term Ventricular Synchrony and Left Ventricular Performance, Unlike Conventional Right Ventricular Apical Pacing. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology, 15, 546-553. &lt;br&gt;https://doi.org/10.1093/europace/eus313</mixed-citation></ref><ref id="hanspub.44230-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Zanon, F., Bacchiega, E., Rampin, L., et al. (2008) Direct His Bundle Pacing Preserves Coronary Perfusion Compared with Right Ventricular Apical Pacing: A Prospective, Cross-Over Mid-Term Study. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology, 10, 580-587. &lt;br&gt;https://doi.org/10.1093/europace/eun089</mixed-citation></ref><ref id="hanspub.44230-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Vijayaraman, P., Dandamudi, G., Subzposh, F.A., et al. (2021) Imaging-Based Localization of His Bundle Pacing Electrodes Results from the Prospective IMAGE-HBP Study. JACC: Clinical Electrophysiology, 7, 73-84.  
&lt;br&gt;https://doi.org/10.1016/j.jacep.2020.07.026</mixed-citation></ref><ref id="hanspub.44230-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Molina-Lerma, M., Macías-Ruiz, R., Sánchez-Millán, P., et al. (2021) Comparative Analysis of His-Bundle Pacing and Left Bundle Branch Area Pacing: Acute and Short-Term Results. Revista Española de Cardiología, 74, 628-630.</mixed-citation></ref><ref id="hanspub.44230-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Huang, W., Su, L., Wu, S. et al. (2017) A Novel Pacing Strategy with Low and Stable Output: Pacing the Left Bundle Branch Immediately beyond the Conduction Block. The Canadian Journal of Cardiology, 33, 1736.e1-1736.e3.  
&lt;br&gt;https://doi.org/10.1016/j.cjca.2017.09.013</mixed-citation></ref><ref id="hanspub.44230-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Vijayaraman, P., Ponnusamy, S.S., Cano, Ó., et al. (2021) Left Bundle Branch Area Pacing for Cardiac Resynchronization Therapy: Results from the International LBBAP Collaborative Study Group. JACC. Clinical Electrophysiology, 7, 135-147. &lt;br&gt;https://doi.org/10.1016/j.jacep.2020.08.015</mixed-citation></ref><ref id="hanspub.44230-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Kleemann, T., Becker, T., Doenges, K., et al. (2007) Annual Rate of Transvenous Defibrillation Lead Defects in Implantable Cardioverter-Defibrillators over a Period of &gt;10 Years. Circulation, 115, 2474-2480.  
&lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.106.663807</mixed-citation></ref><ref id="hanspub.44230-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Knops, R.E., Olde Nordkamp, L.R.A., Delnoy, P.-P.H.M., et al. (2020) Subcutaneous or Transvenous Defibrillator Therapy. The New England Journal of Medicine, 383, 526-536. &lt;br&gt;https://doi.org/10.1056/NEJMoa1915932</mixed-citation></ref><ref id="hanspub.44230-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Gold, M.R., Lambiase, P.D., El-Chami, M.F., et al. (2021) Primary Results from the Understanding Outcomes with the S-ICD in Primary Prevention Patients with Low Ejection Fraction (UNTOUCHED) Trial. Circulation, 143, 7-17.</mixed-citation></ref><ref id="hanspub.44230-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Wherry, K., Stromberg, K., Hinnenthal, J.A., et al. (2020) Using Medicare Claims to Identify Acute Clinical Events Following Implantation of Leadless Pacemakers. Pragmatic and Observational Research, 11, 19-26.  
&lt;br&gt;https://doi.org/10.2147/POR.S240913</mixed-citation></ref></ref-list></back></article>